Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-02-21
1999-01-19
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514345, 514357, A61K 3144
Patent
active
058614230
ABSTRACT:
Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds include
REFERENCES:
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5227391 (1993-07-01), Caldwell et al.
patent: 5242935 (1993-09-01), Lippiello et al.
patent: 5346906 (1994-09-01), Baker et al.
patent: 5559124 (1996-09-01), Bencherif et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5616716 (1997-04-01), Dull et al.
Henrich et al.; "Microcirculatory Effects of Nicotine and Related Alkaloids"; Klin Wochenchr, 62(II):92-100 (1984).
Gibson et al.; "Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments"; J. Med. Chem., 39:4065-4072 (1996).
Wilson, Jr. et al.; "Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine"; J. of Pharmacology and Exper. Therapeutics, 196(3):685-696 (1976).
Baron; "Cigarette smoking and Parkinson's Disease"; Neurology, 36:1490-1496 (1986).
Decina et al.; "Cigarette Smoking and Neuroleptic-Induced Parkinsonism"; Biol. Psychiatry, 28(6):502-508 (1990).
Faraone et al.; "An Exploratory Study of ADHD among Second-Degree Relatives of ADHD Children"; Biol. Psychiatry, 35(6):398-402 (1994).
Giacobini; "Pharmacotherapy of Alzheimer's Disease: New Drugs and Novel Strategies"; Therapeutics, 61:529-538 (1993).
Hall et al.; "Effects of Nicotine on the Release of .sup.3 H-Noradrenaline from the Hypothalamus"; Biochemical Pharmacology, 21:1829-1838 (1972).
Hamon: "Neuropharmacology of anxiety: perspectives and prospects"; TiPS, 15:36-39 (1994).
Harsing, Jr. et al.; "Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization"; J. of Neurochemistry, 59(1):48-54 (1992).
Newhouse et al.; "The role of nicotine and nicotinic mechanisms in neuropsychiatric disease"; British J. of Addiction, 86:521-526 (1991).
Onaivi et al.; "Chronic Nicotine Reverses Age-Associated Increases in Tail-Flick Latency and Anxiety in Rats"; Life Sciences, 54(3):193-202 (1994).
Pomerleau et al.; "The Effects of Cigarette Smoking on Pain and Anxiety"; Addictive Behaviors, 9:265-271 (1984).
Rapier et al.; "Stereoselective Nicotine-Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation"; J. Neurochem., 50(4):1123-1130 (1988).
Rowell; "Current Concepts on the Effects of Nicotine on Neurotransmitter Release in the Central Nervous System"; Adv. Behav. Biol., 31:191-208 (1987). from Mouse Cerebral Cortical Synaptosomes"; J. Neurochem., 43(6):1593-1598 (1984).
Sandor et al.; "Effect of Nicotine on dopaminergic-cholinergic interaction in the striatum"; Brain Res., 567:313-316 (1991).
Sherwood; "Effects of Nicotine on Human Psychomoter Performance"; Human Psychopharmacology, 8:155-184 (1993).
Sjak-Shie et al.; "Effects of chronic nicotine and pilocarpine in nucleus basalis lesioned rats"; Brain Res., 624:295-298 (1993).
Toth et al.; "Effect of Nicotine of Extracellular Levels of Neurotransmitters Assessed by Microdialysis in Various Brain Regions"; Neurochem. Res., 17(3):265-271 (1992).
Vizi; "Acetylcholine release from guinea-pig ileum by parasymathetic ganglion stimulants and gastrin-like polypeptides"; Br. J. Pharmac., 47:765-777 (1973).
Wagner et al.; "Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids?"; Pharmacopsychiat., 21:302-303 (1988).
Lippiello et al.; "RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization"; J. Pharmacol. Exper. Therapeutics, 279(3):1422-1429 (1996).
Bencherif et al.; "RJR-2403: A Nicotinic Agonsist with CNS Selectivity I: In Vitro Characterization"; J. Pharmacol. Exper. Therapeutics, 279(3):1413-1421 (1996).
Hery et al.; "Control of the Release of Newly Synthetized 3H-5-Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat Hypothalamic Slices"; Naunyn-Schmiedeberg's Arch. Pharmacol., 296:91-97 (1977).
Pullan et al.; "Transdermal Nicotine for Active Ulcerative Colitis"; New England J. Med., 330(12):811-815 (1994).
Frank et al.; "Palladium-Catalyzed Vinylic Substitution Reactions with Heterocyclic Bromides"; J. Org. Chem., 43(15):2947-2949 (1978).
Abstract S39: Sanberg et al.; "Beneficial Effects of Nicotine in Tourette's Syndrome"; Int'l Symposium on Nicotine: The Effects of Nicotine on Biological Systems II, Montreal Canada, Jul. 21-24, 1994.
Bencherif Merouane
Caldwell William Scott
Dull Gary Maurice
Lippiello Patrick Michael
LandOfFree
Pharmaceutical compositions incorporating aryl substituted olefi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions incorporating aryl substituted olefi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions incorporating aryl substituted olefi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1247030